Logo

Gene Logic's Q3 Revenues Increase 22 Percent as Losses Narrow 70 Percent

Oct 24, 2007
NEW YORK (GenomeWeb News) — Gene Logic today said third-quarter revenues rose 22 percent as R&D spending increased 4 percent and net loss narrowed by 70 percent.
 
Total receipts for the three months ended Sept. 30 rose to $4.5 million from $3.7 million year over year and came largely from the company’s genomic-services business, which posted flat revenues compared to the same quarter in 2006. Receipts from the company’s drug-repositioning business swelled to $841,000 from $6,000 in the year-ago period.
 
R&D spending increased to $2.7 million from $2.6 million year over year.
 
Gene Logic said net loss decreased to $7.9 million from $26.7 million in the year-ago period.  
 
As of Sept. 30, Gene Logic, which last week said it will sell its genomic assets to Ocimum Biosolutions for $10 million, had $22.6 million in cash and equivalents and $8.9 million in marketable securities.

Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.